archive
02-01 Synthon obtains European approvals for Ibandronate injectable
13-12 Synthon filed Glatiramer acetate dossier in the US
01-11 Synthon appoints Dr. Ian Anderson as Chief Scientific Officer and Dr. Leon Hooftman as Chief Medical Officer
14-09 Meet us at CPhI 2011 in Frankfurt
05-07 Synthon obtains European approvals for two Levetiracetam products
23-06 Synthon acquires Syntarga and its Antibody-Drug Conjugate Technology
31-05 Synthon and MIVAC Development exclusive research collaboration and commercial licensing agreement in MS
20-05 Synthon opens state-of-the-art laboratory for biotechnology
18-05 Perrigo’s partner Synthon receives FDA tentative aprroval for Levocetirizine solution
15-12 Synthon announces European approvals for Exemestane tablets
29-11 Perrigo and Synthon announce FDA final approval and launch of the generic version of Xyzal®
18-11 Synthon announces European approvals for Tamsulosin tablets
14-10 Synthon announces European approvals for Ibandronic acid
26-04 Synthon to accelerate investment in Biosimilars and Novel Biologicals
26-04 Synthon Receives Final Approval for Tamsulosin, AB-rated to Flomax
02-04 Synthon announces tentative approval of generic Amlodipine-Valsartan tablets
22-03 Synthon First Generic Filer for Tadalafil 20 mg
10-03 Meet Synthon at the C2W Career Expo 2010 in Utrecht, the Netherlands
08-03 Synthon completes acquisition of Nafar Laboratorios
08-02 Synthon appoints Rudy Mareel as Chief Executive Officer
20-10 Synthon announces European approvals for Raloxifene
10-09 Synthon at CPhI 2009 in Madrid
21-07 Synthon announces European approvals for generic Rivastigmine
06-07 Synthon receives final approval for Bicalutamide 50mg
20-05 Synthon first generic filer for Xyzal oral solution
04-03 European approvals for Levocetirizine
12-02 Synthon announces European approvals for generic Montelukast